Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Heron Therapeutics (NASDAQ:HRTX) and maintained a $5 price target.
September 25, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Heron Therapeutics and maintained a $5 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $5 price target by Needham suggests a positive outlook for Heron Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100